Atossa Therapeutics Successfully Regains Compliance with Minimum Bid Price Rule
Monday, 18 March 2024, 12:40
Atossa Therapeutics Complies with Nasdaq Minimum Bid Price Requirements
Atossa Therapeutics has successfully met the minimum bid price requirement specified by Nasdaq, showcasing its dedication to regulatory compliance.
A Boost for ATOS Stock
The news of compliance has led to a 0.75% surge in the premarket trading of ATOS stock, indicating investor optimism.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.